KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash from Financing Activities (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Cash from Financing Activities for 13 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 15.41% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, down 89.0% year-over-year, with the annual reading at $5.7 million for FY2025, 89.0% down from the prior year.
  • Cash from Financing Activities hit $1.6 million in Q4 2025 for Arbutus Biopharma, up from $844000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $59.1 million in Q4 2021 to a low of $113000.0 in Q2 2022.
  • Historically, Cash from Financing Activities has averaged $12.9 million across 5 years, with a median of $4.5 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: soared 4096.46% in 2023 and later tumbled 98.14% in 2025.
  • Year by year, Cash from Financing Activities stood at $59.1 million in 2021, then tumbled by 81.25% to $11.1 million in 2022, then crashed by 65.65% to $3.8 million in 2023, then crashed by 62.67% to $1.4 million in 2024, then grew by 15.41% to $1.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ABUS at $1.6 million in Q4 2025, $844000.0 in Q3 2025, and $453000.0 in Q2 2025.